Furthermore, the CD8+ T-cells (CD45+, TCRβ+/CD8+, CD4−) expressed greater amounts of granzyme B molecules in the CpG group and CpG/aOX40 group, compared to the isotype treated tumors (Fig. 4g), suggesting that the specific treatments increased CD8 T-cell functionality and ability to initiate tumor killing. This evidence concerns the gene PTPRC and neoplasm.